News - Gilde Healthcare

Nieuws

Nieuws

Nieuws
Venture&Growth

Nieuws
Private Equity

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...

5 augustus 2025

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000...

31 juli 2025

Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neuro-imaging

Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy...

8 juli 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...

5 augustus 2025

Filter & zoek

Zoek:
Loading...
Dit waren alle artikelen
482baf2551